Cancel anytime
Kazia Therapeutics Ltd ADR (KZIA)KZIA
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/20/2024: KZIA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: -30.8% | Upturn Advisory Performance 2 | Avg. Invested days: 43 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/20/2024 |
Type: Stock | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: -30.8% | Avg. Invested days: 43 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/20/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 24.43M USD |
Price to earnings Ratio - | 1Y Target Price 19.15 |
Dividends yield (FY) - | Basic EPS (TTM) -6.61 |
Volume (30-day avg) 172429 | Beta 2.08 |
52 Weeks Range 1.87 - 15.80 | Updated Date 11/20/2024 |
Company Size Small-Cap Stock | Market Capitalization 24.43M USD | Price to earnings Ratio - | 1Y Target Price 19.15 |
Dividends yield (FY) - | Basic EPS (TTM) -6.61 | Volume (30-day avg) 172429 | Beta 2.08 |
52 Weeks Range 1.87 - 15.80 | Updated Date 11/20/2024 |
Earnings Date
Report Date 2024-10-30 | When BeforeMarket |
Estimate - | Actual - |
Report Date 2024-10-30 | When BeforeMarket | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -99999999.99% |
Management Effectiveness
Return on Assets (TTM) -46.42% | Return on Equity (TTM) -186.37% |
Revenue by Products
Revenue by Products - Current and Previous Year
Revenue by Geography
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 18340248 | Price to Sales(TTM) 43627.37 |
Enterprise Value to Revenue 12.21 | Enterprise Value to EBITDA -0.71 |
Shares Outstanding 3328510 | Shares Floating 249564699 |
Percent Insiders - | Percent Institutions 7.06 |
Trailing PE - | Forward PE - | Enterprise Value 18340248 | Price to Sales(TTM) 43627.37 |
Enterprise Value to Revenue 12.21 | Enterprise Value to EBITDA -0.71 | Shares Outstanding 3328510 | Shares Floating 249564699 |
Percent Insiders - | Percent Institutions 7.06 |
Analyst Ratings
Rating 4 | Target Price 1.99 | Buy 1 |
Strong Buy - | Hold - | Sell - |
Strong Sell - |
Rating 4 | Target Price 1.99 | Buy 1 | Strong Buy - |
Hold - | Sell - | Strong Sell - |
AI Summarization
Kazia Therapeutics Ltd ADR: A Comprehensive Overview
Company Profile
History and Background
Kazia Therapeutics Limited (Kazia) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for cancer. The company was founded in 2008 and is headquartered in Melbourne, Australia, with a US subsidiary in San Francisco, California.
Kazia's journey began with the development of GDC-0077, a small molecule inhibitor targeting PI3K/AKT/mTOR signaling pathways in cancer. While GDC-0077 did not achieve its primary endpoint in a Phase III trial, it provided valuable insights that led to the development of Kazia's current pipeline of targeted therapies.
Core Business Areas
Kazia's core business areas include:
- Developing novel therapies for cancer: The company focuses on oncology treatments with unmet needs, particularly those targeting DNA damage response pathways and immune modulation.
- Partnering with leading research institutions: Kazia collaborates with academic and research centers to access cutting-edge technologies and accelerate drug development.
- Leveraging its intellectual property portfolio: Kazia actively protects its intellectual property through patents and licenses, ensuring its competitive advantage.
Leadership Team and Corporate Structure
Kazia's leadership team comprises experienced professionals with expertise in oncology drug development, clinical research, and business leadership.
- Dr. James Garner - Chief Executive Officer & Managing Director: Dr. Garner has over 20 years of experience in the pharmaceutical industry, leading clinical development programs and securing licensing deals.
- Dr. Michael O'Neill - Chief Medical Officer: Dr. O'Neill has extensive experience in clinical oncology research and development, having held leadership positions in global pharmaceutical companies.
- Dr. Richard Godfrey - Chief Scientific Officer: Dr. Godfrey has a distinguished career in cancer research, having contributed to multiple oncology drug development programs.
Kazia's corporate structure consists of a Board of Directors responsible for overseeing the company's strategic direction and a Management Team responsible for executing day-to-day operations.
Top Products and Market Share
Products and Offerings
Kazia's current pipeline focuses on two lead drug candidates:
- Paxalisib (formerly GDC-0077): A small molecule inhibitor targeting PI3K/AKT/mTOR signaling pathways, currently in Phase II trials for glioblastoma and pancreatic cancer.
- Evasin-1: A synthetic peptide targeting the PD-1/PD-L1 pathway, currently in Phase I trials for the treatment of solid tumors.
Market Share
Kazia's lead candidates are still in clinical development and haven't reached the market yet. Therefore, they currently hold no market share. However, the potential market for these drugs is significant.
- Glioblastoma: This aggressive brain tumor has a high unmet medical need, with current treatment options offering limited survival benefits.
- Pancreatic cancer: This highly lethal cancer has a dismal prognosis, with a five-year survival rate of less than 10%.
Product Performance and Market Reception
Clinical trial data for Paxalisib and Evasin-1 is still emerging. Early results have shown promising signs of efficacy and safety, but further data is needed to assess their full potential and market reception.
Total Addressable Market
The global oncology market is estimated to reach over $200 billion by 2025, with continued growth driven by rising cancer prevalence, aging population, and technological advancements. The specific markets for Paxalisib and Evasin-1, glioblastoma and pancreatic cancer, represent significant segments within the broader oncology market.
Financial Performance
Kazia is currently a pre-revenue company, meaning it generates no income from product sales. Its primary source of funding comes from public offerings, private placements, and research grants.
Revenue and Net Income
Kazia's revenue and net income are currently negative, reflecting its pre-revenue status and expenses associated with research and development activities.
Profit Margins and EPS
Similarly, Kazia does not report profit margins or earnings per share (EPS) due to its absence of revenue.
Cash Flow Statements and Balance Sheet Health
Kazia's cash flow statements reflect its reliance on funding from external sources. The company's balance sheet health is impacted by its ongoing expenses and limited revenue.
Dividends and Shareholder Returns
Kazia does not currently pay dividends due to its pre-revenue status. Shareholder returns have been negative in recent years, reflecting the company's early-stage development and lack of commercialized products.
Growth Trajectory
Kazia's growth trajectory is heavily dependent on the success of its clinical trials and potential market approval of its lead drug candidates. If successful, the company could experience significant revenue growth and market share expansion.
Market Dynamics
The oncology market is highly competitive, with numerous established players and emerging companies vying for market share. Kazia's success will depend on its ability to differentiate its products through efficacy, safety, and unique mechanisms of action.
Competitors
Kazia's key competitors in the oncology space include:
- Merck & Co. (MRK): A major pharmaceutical company with a broad portfolio of oncology treatments, including Keytruda (pembrolizumab) for various cancers.
- Bristol Myers Squibb (BMY): Another leading pharmaceutical company with a strong oncology presence, offering drugs like Opdivo (nivolumab) for several cancer types.
- Roche Holding AG (RHHBY): A global healthcare giant with a diverse oncology portfolio, including Avastin (bevacizumab) for various cancers.
Potential Challenges and Opportunities
Challenges
Kazia faces several challenges, including:
- Clinical trial success: The company's future depends on the successful completion of its clinical trials and potential market approval of its lead drug candidates.
- Competition: The oncology market is highly competitive, and Kazia needs to differentiate its products to gain market share.
- Funding: The company requires additional funding to support its ongoing research and development activities.
Opportunities
Kazia has several opportunities for growth, including:
- Large addressable market: The oncology market offers significant potential for revenue growth if the company successfully commercializes its products.
- Unmet medical needs: Kazia's lead drug candidates target cancers with high unmet medical needs, potentially leading to significant market demand.
- Strategic partnerships: Kazia can leverage partnerships with larger pharmaceutical companies to accelerate development and commercialization efforts.
Recent Acquisitions (last 3 years)
Kazia has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating
Due to limited financial data and lack of commercialized products, assigning a precise AI-based fundamental rating is challenging. However, based on the company's market capitalization, growth potential, and pipeline progress, a preliminary rating of 6-7 out of 10 could be considered. This rating reflects Kazia's early-stage development but acknowledges its promising pipeline and potential for significant future growth.
Sources and Disclaimers
This overview is based on information gathered from the following sources:
- Kazia Therapeutics Ltd. website (https://www.kaziatherapeutics.com/)
- Securities and Exchange Commission (SEC) filings
- Market research reports
- Financial news articles
This information is provided for informational purposes only and should not be considered financial advice. Investing in early-stage companies like Kazia carries inherent risks, and potential investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kazia Therapeutics Ltd ADR
Exchange | NASDAQ | Headquaters | Sydney, NSW, Australia |
IPO Launch date | 1999-01-06 | CEO, MD & Director | Dr. John Edwin Friend II, M.D. |
Sector | Healthcare | Website | https://www.kaziatherapeutics.com |
Industry | Biotechnology | Full time employees | - |
Headquaters | Sydney, NSW, Australia | ||
CEO, MD & Director | Dr. John Edwin Friend II, M.D. | ||
Website | https://www.kaziatherapeutics.com | ||
Website | https://www.kaziatherapeutics.com | ||
Full time employees | - |
Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.